Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Typically, autosomal dominant familial hypercholesterolaemia (FH) is caused by mutations in the low density lipoprotein (LDL) receptor or apolipoprotein B genes that result in defective clearance of plasma LDL by the liver, but a third gene (PCSK9), encoding a putative proprotein convertase, has recently been implicated. Two independent microarray studies support a role for PCSK9 in sterol metabolism and adenoviral-mediated over-expression of PCSK9 in mouse liver depletes hepatic LDL-receptor protein, but the mechanism by which dominant mutations cause human FH is unclear. We have identified the D374Y mutant of PCSK9 in three FH families of English origin; all 12 affected individuals have unusually severe hypercholesterolaemia and require more stringent treatment than typical FH patients, who are heterozygous for defects in the LDL receptor. We have stably expressed wild-type (WT) and variant PCSK9 in McArdle-7777 rat hepatoma cells and shown by confocal microscopy that all forms of PCSK9 co-localize with protein disulphide isomerase in the ER whether or not they can be autocleaved. Expression of the proposed pathogenic variants, but not of WT, S386A or F216L PCSK9, increases secretion of apolipoprotein B100-containing lipoproteins from the cells by 2-4-fold probably by reducing the degradation of nascent protein; no differences in LDL-receptor content were observed in cells expressing WT, S386A or F216L PCSK9 and only a small reduction in cells expressing the D374Y or S127R mutants. This suggests that the variants of PCSK9 found in FH influence the secretion of apoB-containing lipoproteins, providing an explanation for the marked increase in circulating LDL in heterozygous carriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191 · cited 4×
“In keeping with this, PCSK9 expressed in heterologous cells in vitro has the ability to autocleave its own propeptide, but the role of its prodomain and the physiological substrates for its proteolytic activity remain unknown (11,16).”
BackgroundInfluentialGarcia, C. K., Wilund, K., Arca, M., Zuliani, G., Fellin, R., Maioli, M., Calandra, S., Bertolini, S., Cossu, F., Grishin, N., et al. (2001) · Science · doi:10.1126/science.1060458 · Cited by 624 · cited 8×
“Although there is evidence of mild hypercholesterolaemia in a few heterozygous carriers, mutations in ARH are unlikely to be a common underlying cause of dominant hypercholesterolaemia (7).”
BackgroundInfluentialChiang, L. W., Grenier, J. M., Ettwiller, L., Jenkins, L. P., Ficenec, D., Martin, J., Jin, F., DiStefano, P. S., & Wood, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051630598 · Cited by 108 · cited 1×
“The PCSK9 gene product was first identified as a protein whose expression was increased in neuronal cells after injuries that induce apoptosis (14).”
BackgroundBurden, J. J., Sun, X.-M., García, A. B. G., & Soutar, A. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313689200 · Cited by 82
Self-citation
Cited by
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Zhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 632
Molecular biology of PCSK9: its role in LDL metabolism
HORTON, J., COHEN, J., & HOBBS, H. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.12.008 · Cited by 621
Mechanisms of disease: genetic causes of familial hypercholesterolemia
Soutar, A. K., & Naoumova, R. P. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0836 · Cited by 608
Self-citationA Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol
Kotowski, I. K., Pertsemlidis, A., Luke, A., Cooper, R. S., Vega, G. L., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/500615 · Cited by 517
“An alternative hypothesis is that PCSK9 affects plasma LDL-C levels by altering the rate of secretion of apoB-100 in an LDLR-independent manner (Benjannet et al. 2004; Ouguerram et al. 2004; Sun et al. 2005).”
BackgroundOxidized low-density lipoprotein as a biomarker of cardiovascular diseases
Trpkovic, A., Resanovic, I., Stanimirovic, J., Radak, D., Mousa, S. A., Cenic-Milosevic, D., Jevremovic, D., & Isenovic, E. R. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2014.992063 · Cited by 321
Costet, P., Cariou, B., Lambert, G., Lalanne, F., Lardeux, B., Jarnoux, A.-L., Grefhorst, A., Staels, B., & Krempf, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508582200 · Cited by 304
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Humphries, S. E., Whittall, R. A., Hubbart, C. S., Maplebeck, S., Cooper, J. A., Soutar, A. K., Naoumova, R., Thompson, G. R., Seed, M., Durrington, P. N., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.038356 · Cited by 267
Self-citationEffect of mutations in the PCSK9 gene on the cell surface LDL receptors
Cameron, J., Holla, Ø. L., Ranheim, T., Kulseth, M. A., Berge, K. E., & Leren, T. P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl077 · Cited by 258
“However, studies of transgenic mice and transfected hepatocyte cell lines have provided conflicting data regarding the effect of gain-of-function mutations on secretion of apolipoprotein B (7,8,10,18).”
BackgroundMethodInfluentialFerri, N., Tibolla, G., Pirillo, A., Cipollone, F., Mezzetti, A., Pacia, S., Corsini, A., & Catapano, A. L. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.026 · Cited by 258
Abifadel, M., Rabès, J.-P., Devillers, M., Munnich, A., Erlich, D., Junien, C., Varret, M., & Boileau, C. (2009) · Human Mutation · doi:10.1002/humu.20882 · Cited by 256
Berge, K. E., Ose, L., & Leren, T. P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000204337.81286.1c · Cited by 236
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Fisher, T. S., Surdo, P. L., Pandit, S., Mattu, M., Santoro, J. C., Wisniewski, D., Cummings, R. T., Calzetta, A., Cubbon, R. M., Fischer, P. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701634200 · Cited by 181
The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion
Gustafsen, C., Kjolby, M., Nyegaard, M., Mattheisen, M., Lundhede, J., Buttenschøn, H., Mors, O., Bentzon, J. F., Madsen, P., Nykjaer, A., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.006 · Cited by 170
“, 2012) and that a gain-of-function PCSK9 mutant dramatically increases ApoB100 secretion (Sun et al., 2005).”
BackgroundSundaram, M., & Yao, Z. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-35 · Cited by 154
Targeting PCSK9 for hypercholesterolemia
Norata, G. D., Tibolla, G., & Catapano, A. L. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-140025 · Cited by 127
Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xia, X.-D., Peng, Z.-S., Gu, H.-M., Wang, M., Wang, G.-Q., & Zhang, D.-W. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.764038 · Cited by 125
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
Tavori, H., Rashid, S., & Fazio, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.017 · Cited by 86
“7 One area of study that is gaining traction is the effect of PCSK9 on lipoprotein assembly and secretion, with emerging evidence having identified effects of PCSK9 on triglyceride-rich lipoproteins (TRL), an additional lipid risk factor for coronary heart disease (39, 54, 55).”
Homer, V. M., Marais, A. D., Charlton, F., Laurie, A. D., Hurndell, N., Scott, R., Mangili, F., Sullivan, D. R., Barter, P. J., Rye, K.-A., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.022 · Cited by 84
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Unexpected roles for PCSK9 in lipid metabolism
Soutar, A. K. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834622b5 · Cited by 39
Self-citationLei, J. (2014) · Medical Science Monitor · doi:10.12659/msm.892091 · Cited by 32
“PCSK9 may also regulate apolipoprotein B-containing lipoprotein production and apoB secretion [26,27].”
BackgroundElbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J.-P., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1206080 · Cited by 29
Ruotolo, A., Di Taranto, M. D., D’Agostino, M. N., Marotta, G., Gentile, M., Nunziata, M., Sodano, M., Di Noto, R., Del Vecchio, L., Rubba, P., et al. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0144 · Cited by 18
Metadata
- Authors
- Sun, X.-M., Eden, E. R., Tosi, I., Neuwirth, C. K., Wile, D., Naoumova, R. P., & Soutar, A. K.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03-16
- Volume
- 14
- Issue
- 9
- Pages
- 1161-1169
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2116970126
- Cited by
- 150
- References
- 6
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.